

Clinical Trial Protocol

Iranian Registry of Clinical Trials

15 Jul 2026

Evaluation of Atomoxetine efficacy on Freezing of gait in patient with Parkinson

Protocol summary

Study aim

Evaluation of Atomoxetine efficacy on Freezing of gait in patient with Parkinson referred to Ahvaz Golestan hospital in a period six month in 2021

Design

A total of 32 patients of both sexes and all age groups will be randomly selected from Parkinson's patients referred to Ahvaz Golestan Hospital in a period of 6 months in 1400 who had frozen gait. Group A includes 16 patients, which an uninformed person randomly selected.

Settings and conduct

Blinding will be done by recording atomoxetine and placebo by a person who has no information about the patient group. Thirty-two Parkinson's patients referred to Golestan Hospital in Ahvaz for a period of 6 months in 1400 who suffered from frozen gait were randomly selected by an uninformed person and treated with atomoxetine at a dose of 40 mg for 2 weeks and then Dose increases to 80 mg for six weeks.

Participants/Inclusion and exclusion criteria

Entry 1. Diagnosis of Parkinson's disease based on examination and history 2. Patients with stage 2-4 of Hoehn and yahr scale; 3. Normal tests (vitamin B12, thyroid, liver and kidney tests) 4. Levodopa treatment for at least 3 months before the study 5. Ability to walk at least 20 steps without the use of assistive devices No entry 1. Continued use of stimulants (STIMULANT) 2. Contraindications to the use of atomoxetine

Intervention groups

Patient with Parkinson referred to Ahvaz Golestan hospital

Main outcome variables

Age; Gender; Duration of illness; drug side effects; Follow-up time

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20211008052695N1**

Registration date: **2021-11-17, 1400/08/26**

Registration timing: **registered_while_recruiting**

Last update: **2021-11-17, 1400/08/26**

Update count: **0**

Registration date

2021-11-17, 1400/08/26

Registrant information

Name

Esmat Ramezanirad

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 61 3441 0975

Email address

d.r.ramezanirad@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-09-23, 1400/07/01

Expected recruitment end date

2022-03-20, 1400/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of Atomoxetine efficacy on Freezing of gait in patient with Parkinson

Public title

Evaluation of Atomoxetine efficacy on Freezing of gait in patient with Parkinson	
Purpose	Treatment
Inclusion/Exclusion criteria	
Inclusion criteria:	1) Diagnosis of Parkinson's disease based on examination and history 2) Patients with stage 2-4 of Hoehn and yahr scale; 3) Normal tests (vitamin B12, thyroid, liver, and kidney tests) 4) Levodopa treatment for at least 3 months before the study 5) Ability to walk at least 20 steps without the use of assistive devices
Exclusion criteria:	
Age	No age limit
Gender	Both
Phase	3
Groups that have been masked	• Participant • Care provider • Investigator • Outcome assessor • Data analyser • Data and Safety Monitoring Board
Sample size	Target sample size: 32
Randomization (investigator's opinion)	Randomized
Randomization description	This study is a randomized controlled clinical trial. In this study, patients will be assigned to each treatment group using a randomized block method using four blocks in this study. Blocking is used to balance the number of samples assigned to each of the study groups. This feature helps to equate the number of samples assigned to each of the study groups in cases where intermediate analyzes are required during the sampling process. The blinding method will also be used to prevent the allocation from being disclosed in each block. This study will be double-blind. The correction will be performed by recording atomoxetine and placebo by a person who has no information about the patient group. A total of 32 patients of both sexes and all age groups were randomly selected from Parkinson's patients referred to Ahvaz Golestan Hospital in 6 months in 1400 who had frozen gait and were treated with levodopa. Hoehn and yahr scale divisions in groups 2 to 4 will be included in the study. Group A consists of 16 patients randomly selected by an uninformed person and treated with atomoxetine 40 mg for two weeks and then increased the dose to 80 mg for six weeks. Group B consists of 16 patients who are randomly selected by an uninformed person and are treated with a placebo similar to group A. The first visit will be on the first day before starting treatment and determining the score of the FOGQ questionnaire and starting the medication. This questionnaire consists of 6 questions, each of which receives a score of 0 to 4, and the minimum score is 0, and the maximum is 24. The second visit will take place two weeks after treatment, and the third visit will take place six weeks after the second visit. The score of the FOGQ questionnaire will be prepared from the patient, and finally, the data will be analyzed by SPSS statistical software version 22. The FOGQ questionnaire is a questionnaire that assesses the freezing of gait in Parkinson's patients. Giladi introduced this questionnaire in 1999. Giladi calculated the validity and reliability of this questionnaire on 40 patients with Parkinson's disease. Using Cronbach's alpha, 94% was obtained, and the validity rate for this questionnaire was 70% (Giladi article reference). In Iran, this questionnaire was translated by Taghizadeh in 2021. He used the questionnaire for 115 patients with Parkinson's disease. Cronbach's alpha was 92% (Taghizadeh article).
Blinding (investigator's opinion)	Double blinded
Blinding description	Blinding will be done by recording atomoxetine and placebo by a person who has no information about the patient group. A total of 32 patients of both sexes and all age groups were randomly selected from Parkinson's patients referred to Ahvaz Golestan Hospital in a period of 6 months in 1400 who had frozen gait and were treated with levodopa. The Hoehn and yahr scale divisions in categories 2 to 4 will be included in the study.
Placebo	Used
Assignment	Parallel
Other design features	
Secondary Ids	empty
Ethics committees	
1	
Ethics committee	
Name of ethics committee	Research Ethics Committees of Golestan Hospital
Street address	No. 9, 9 Resalat Ave., NIDC Complex
City	ahwaz
Province	Khouzestan
Postal code	6166648791
Approval date	2021-04-13, 1400/01/24
Ethics committee reference number	IR.AJUMS.HGOLESTAN.REC.1400.026
Health conditions studied	
1	
Description of health condition studied	

Parkinson disease
ICD-10 code
G21.9
ICD-10 code description
Secondary parkinsonism, unspecified

Primary outcomes

1

Description

Freezing of gait in patient with Parkinson

Timepoint

Patients are treated with atomoxetine at a dose of 40 mg for 2 weeks and then increase the dose to 80 mg for six weeks.

Method of measurement

The first visit will be on the first day and before starting treatment, determining the FOGQ questionnaire's score, and starting the medication. This questionnaire consists of 6 questions, each of which receives a score of 0 to 4, and the minimum score is 0, and the maximum is 24. The second visit will take place two weeks after the start of treatment, and the third visit will take place 6 weeks after the second visit.

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Group A includes 16 patients randomly selected by an uninformed person and treated with atomoxetine 40 mg for 2 weeks and then increase the dose to 80 mg for six weeks.

Category

Treatment - Drugs

2

Description

Control group: Group B includes 16 patients who are randomly selected by an uninformed person and are treated with a placebo similar to group A.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Ahwaz Golestan Hospital

Full name of responsible person

Seyed Ehsan Mohamadianinejad

Street address

No. 9, 9 Resalat Ave., NIDC Complex

City

Ahwaz

Province

Khouzestan

Postal code

6166648791

Phone

+98 61 3441 0975

Email

d.r.ramezanirad@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Seyed Ehsan Mohamadianinejad

Street address

Farvardin Ave., Golestan Hospital., Golestan

City

Ahwaz

Province

Khouzestan

Postal code

6136763316

Phone

+98 61 3320 4531

Email

D.R.ramezanirad@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ahvaz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Seyed Ehsan Mohamadianinejad

Position

Professor

Latest degree

Subspecialist

Other areas of specialty/work

Neurology

Street address

Farvardin Ave., Golestan Hospital., Golestan

City

Ahwaz

Province

Khouzestan

Postal code

6136763316

Phone

+98 61 3320 4531

Email

D.R.ramezanirad@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

Full name of responsible person

Seyed Ehsan Mohamadianinejad

Position

Professor

Latest degree

Subspecialist

Other areas of specialty/work

Neurology

Street address

Farvardin Ave., Golestan Hospital., Golestan

City

Ahwaz

Province

Khouzestan

Postal code

6136763316

Phone

+98 61 3441 0975

Email

D.R.ramezanirad@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

Full name of responsible person

Seyed Ehsan Mohamadianinejad

Position

Professor

Latest degree

Subspecialist

Other areas of specialty/work

Neurology

Street address

Farvardin Ave., Golestan Hospital., Golestan

City

Ahwaz

Province

Khouzestan

Postal code

6136763316

Phone

+98 61 3441 0975

Email

d.r.ramezanirad@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

After the analysis, the study results are presented to all study participants in the form of a file.

When the data will become available and for how long

Start of the access period from the end of 1400 for 6 months after the end of printing the results

To whom data/document is available

Researchers and participants

Under which criteria data/document could be used

Access to the data is not an obstacle if the participants' personal details are distorted.

From where data/document is obtainable

Responsible person - 09163439107

What processes are involved for a request to access data/document

Contact the project manager - review the application - register and submit

Comments